Fisetin’s poor water solubility is one of the most consistent limitations named across its research literature, which has pushed supplement makers toward liposomal and phytosomal (“phospholipid complex”) formulations that promise dramatically better absorption. The animal pharmacokinetic data behind these claims is real and, in some cases, striking. Whether it translates into a proportionally better outcome for a person taking an oral capsule is a separate, less settled question.
Key Takeaways
- A 2013 mouse study found liposomal fisetin achieved a 47-fold increase in relative bioavailability compared to free fisetin — but the fisetin was given by intraperitoneal injection, not orally.
- Phytosome (phospholipid complex) technology is a newer, distinct approach that binds fisetin to soy phosphatidylcholine; published research so far has focused on targeted cancer-cell delivery rather than general oral bioavailability in healthy tissue.
- Broader flavonoid nanocarrier research suggests lipid-based systems generally improve bioavailability in the 2-5 fold range for oral dosing, a meaningfully smaller number than the 47-fold injection result often cited in marketing.
- No head-to-head human trial has compared oral liposomal fisetin against standard oral fisetin capsules for blood-level absorption in people.
Why Bioavailability Is Fisetin’s Persistent Problem
Fisetin is a flavonoid with very low aqueous solubility, and oral bioavailability studies consistently describe it as poorly absorbed in its native form — a limitation reviews specifically flag as constraining fisetin’s clinical and supplement-use potential, especially for anything beyond local or high-dose applications[1]. This is the problem enhanced-delivery formulations are trying to solve, and it’s a legitimate one — not a manufactured concern to sell a premium product.
The 47-Fold Number, and Its Important Caveat
The headline statistic behind most liposomal fisetin marketing traces back to a 2013 study in the International Journal of Pharmaceutics, which developed a liposomal fisetin formulation and found it produced a 47-fold increase in relative bioavailability compared to free fisetin, with corresponding improvements in antitumor efficacy in a Lewis Lung Carcinoma mouse model[2]. The detail that gets dropped in marketing copy: this dramatic result was measured after intraperitoneal (injected) administration in mice, not oral dosing. Injection bypasses first-pass liver metabolism and gut absorption entirely, which is precisely where oral fisetin loses most of its bioavailability in the first place — so a 47-fold injection result doesn’t directly predict what an oral liposomal capsule will do in a person’s bloodstream.
What Phytosome Technology Does Differently
Phytosomes are a distinct approach from liposomes: rather than encapsulating fisetin inside a lipid bubble, the compound is chemically complexed with a phospholipid (typically soy phosphatidylcholine) to form a more stable, membrane-compatible molecule. A 2023 study developed a fisetin-phospholipid complex, further engineered into cationic and hyaluronic-acid-modified versions, specifically for targeted delivery to breast cancer cells[3]. This is genuinely novel drug-delivery science, but it was designed and tested for tumor targeting, not for demonstrating general oral bioavailability improvement in a healthy person — a different research question than what a longevity-focused supplement buyer actually needs answered.
What Oral Bioavailability Data Actually Suggests
Broader comparative reviews of flavonoid nanocarrier technology put oral bioavailability improvements from lipid-based delivery systems (solid lipid nanoparticles, nanostructured lipid carriers, and liposomes generally) in a more modest 2-5 fold range, alongside improved cell viability and reduced oxidative stress markers in vitro[4]. That’s still a meaningful improvement over standard capsules if it holds for fisetin specifically taken orally, but it’s a different order of magnitude than the injection-based 47-fold figure, and no published human trial has directly measured oral liposomal fisetin blood levels against standard oral fisetin in the same study.
Practical Takeaway
The mechanistic case for enhanced-delivery fisetin is real — poor bioavailability is a documented, legitimate limitation of standard fisetin, and lipid-based delivery systems are a scientifically sound way to address it. What isn’t yet established is the exact size of that benefit for an oral capsule taken by a person, since the most dramatic bioavailability numbers come from injected animal studies rather than oral human data. If choosing between a standard and liposomal/phytosomal product at a meaningful price difference, it’s reasonable to expect some absorption benefit from the enhanced formulation, but treat marketing claims citing the 47-fold figure with skepticism unless the product’s own data is for oral, not injected, administration.
References
- Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics — bioavailability limitation review.
- Liposomal encapsulation of the natural flavonoid fisetin improves bioavailability and antitumor efficacy. PMID 23380621
- Self-assembled fisetin-phospholipid complex: Fisetin-integrated phytosomes for effective delivery to breast cancer. International Journal of Pharmaceutics (2023).
- Comparative review of flavonoid lipid-based nanocarrier bioavailability data (SLN/NLC/liposome, 2-5 fold oral improvement range).
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
